|Bid||71.00 x 1000|
|Ask||106.21 x 800|
|Day's Range||101.88 - 105.41|
|52 Week Range||86.34 - 142.64|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||33.17|
|Earnings Date||Jan 31, 2022 - Feb 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||138.15|
SOMERSET, N.J., May 27, 2022--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will present at two upcoming investor conferences.
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.